Skip to main content

About

Stacey Tannenbaum, PhD, FISoP is a scientist and leader in Model Informed Drug Development.  She was recently at Metrum Research Group as VP of Scientific Engagement, following 20 years of Pharmacometrics experience in industry from Novartis and Astellas, where she led the US Pharmacometrics group.  Stacey earned a BSE in Biomedical Engineering (Duke University), a PhD in Pharmaceutical Sciences and Applied Mathematics (University of Arizona), and a post-doctoral fellowship at the Center for Drug Development Science (Georgetown University).

Stacey has had significant impact on the global Pharmacometrics community.  She co-founded the International Society of Pharmacometrics (ISoP), serving as its first President and is an ISoP Fellow. Stacey co-founded the American Conference on Pharmacometrics (ACoP) and was conference chair for the first three events; she remains an active volunteer in both ISoP and ACoP. She is the Executive Committee chair for the World Conference on Pharmacometrics (WCoP), and is the chair of the Quantitative Pharmacology Network at the American Society of Clinical Pharmacology and Therapeutics (ASCPT).  She served as a board member of the American Association of Pharmaceutical Scientists (AAPS), chaired the AAPS M&S Focus Group, and was the co-chair for the AAPS Forum for Connecting Predictive Modelers.  Stacey also co-founded the networking group Modeling and Simulation Applications in Clinical Pharmacotherapy (MoSAiC).

Current Positions

  • Communication and Leadership Consultant, Northbrook, IL
  • Assistant Professor, Department of Pharmacy Practice and Science, University of Arizona, Tucson, AZ
  • Adjunct Assistant Professor, Dept. of Pharmaceutical Sciences at University of Tennessee Health Science Center, Memphis, TN
  • Adjunct Professor, of Pharmaceutics and Medicinal Chemistry, Thomas J. Long School of Pharmacy, University of the Pacific, Stockton, CA

Previous Professional Experience

  • Vice President, Scientific Engagement. Metrum Research Group (Apr 2023- Feb 2025)
  • US Group Head, Pharmacometrics. Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development
    • Executive Director (Oct 2021 – Apr 2023)
    • Senior Director (Apr 2017 – Oct 2021)
  • Director: Pharmacokinetics, Modeling, and Simulation. Clinical Pharmacology & Exploratory Development, Astellas Pharma Global Development (Jan 2012 – March 2017)
  • Modeling and Simulation: Pharmacology Modeling Subgroup. Novartis Pharmaceuticals Corporation.
    • Expert Modeler (June 2008 – Nov 2011)
    • Senior Modeler (June 2003 – June 2008)
  • Fellow: International Fellowship in Drug Development and Regulatory Sciences, Center for Drug Development Science (CDDS), Georgetown University Medical Center. (June 2001 – June 2003).
  • Intern: Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration (FDA). (Oct – Dec 2002)

Education

  • Postdoctoral Research Fellowship, Drug Development and Regulatory Science
    • Center for Drug Development Science (CDDS), Georgetown University Medical Center. June 2001-June 2003.
    • Supervisors: Carl C. Peck, M.D., Center Director; Howard Lee, M.D., PhD, Asst. Professor
  • Doctor of Philosophy, Pharmaceutical Sciences (major) and Applied Mathematics (minor)
    • University of Arizona. May 2001.
    • Dissertation title: Pharmacokinetic Principles of Allometry and Allometric, Pharmacokinetic, and Pharmacodynamic Analyses of Cocaine and Ethanol
    • Supervisor: Michael Mayersohn, Ph.D
  • Bachelor of Science in Engineering, Biomedical Engineering.
    • Duke University. May 1993.
  • International (American) Society of Pharmacometrics (ISoP) – 2011 to present
    • Founding Member, Founding Board of Directors
    • President 2011, Past-President 2012-2104
    • Fellow 2014
    • Pharmacometrics Workflow Working Group, part of ISoP Standards and Best Practices Committee (2023-present)
    • Soft Skills and Communication Working Group, part of ISoP Education Committee (2023-present)
    • Statistics and Pharmacometrics SxP Special Interest Group Steering Committee 2018-2023, Pharmacometrics Co-Chair 2020-2022, Past Co-Chair 2022-2023
    • Organizational Effectiveness Committee Member 2019-2020
    • Nomination Committee Member 2016-2022
    • 5-year strategy Steering Committee Member 2018
  • American Conference on Pharmacometrics (ACoP)
    • Co-founder
    • Conference and Organizing Committee Chair: 2008; 2009; 2011
    • Organizing Committee Advisor: 2013, 2022, 2023
    • ACoP12 Pre-Conference Co-Chair 2021
    • Social Committee Chair 2021; member 2020, 2022-2023
  • World Conference on Pharmacometrics (WCoP)
    • Executive Committee Chair 2016-present
    • Executive and Scientific Committee Member 2012-present
    • Executive Committee Advisor 2010-2012
  • MIDD Curriculum Steering Committee (2020- 2023)
    • Development of MIDD training curriculum for FDA CDER reviewers; now publicly available.
    • Cross-organization effort managed by the Critical Path Institute.
  • Modeling and Simulation Applications in Clinical Pharmacotherapy (MoSAiC), local NJ/NY/PA networking group.  Co-founder and Co-Chair 2005-2012
  • Indiana University CTSI Disease and Therapeutic Response Modeling and Simulation Advisory Board member (2018-present)
  • Lake Nona Leadership Council, University of Florida Center for Pharmacometrics and Systems Pharmacology (2018-present)
  • American Association of Pharmaceutical Scientists (AAPS): 1994 to present
    • Executive Council (Board of Directors) Member at Large, 2014-2017
    • Horizon Committee, 2021
    • Predictive Modeling Community Founder and Steering Committee member, 2020-2022; Chair 2021-2022
    • Pharmacometrics Community Steering Committee member, 2018-2023
    • Nominations Committee, 2019
    • Awards Committee, 2016-2019
    • Clinical Pharmacology and Translational Research (CPTR) section: Secretary/Treasurer 2006-2011
    • Modeling and Simulation Focus Group: Chair-Elect 2001-2003, Chair 2003-2005, Past Chair 2005-2007, Steering Committee 2007
    • Quantitative Model Based Drug Development Task Force Member 2006-2011
    • CPTR Outstanding Manuscript in Modeling and Simulation selection committee, 2008, 2009, and 2011
  • American Society of Clinical Pharmacology and Therapeutics (ASCPT): 2001-2005, 2017-present
    • Quantitative Pharmacology (QP) Network Chair Elect 2024-2025, Chair 2025-2026
    • Pharmacometrics & Pharmacokinetics (PMK) Community Steering Committee member 2022-2024
    • Board Nominating Committee 2023
    • Scientific Awards Nomination Task Force 2020-2022
  • American College of Clinical Pharmacology (ACCP): 2000-2005, 2016 – present
  • NLME Consortium (NLMEc) Novartis representative and member of Implementation subteam, 2006
  • Duke University Department of Biomedical Engineering Undergraduate Advisory Board, 2008
  • Toastmasters International
    • mrgtoast (MetrumRG Toastmasters) 2023-2025
    • Astellas Kan Pai Masters 2012-2023
    • Novartis East Hanover Club 2003-2011
    • Offices held: President, Club Coach, Club Mentor, VP of Education, VP of Membership, Sergeant-at-Arms, Mentoring Committee

I am text block. Click edit button to change this text.

  • Title TBA. ISoP Keynote Speaker, Population Approach Group of Australia and New Zealand (PAGANZ), Singapore Sept 2025.
  • Pharmacokinetic/Pharmacodynamic Modeling of Monoclonal Antibodies: A Tool for Decision-Making in Drug Development. Pharmacokinetics and Pharmacodynamics of Protein Therapeutics. University of Tennessee Health Science Center April 2011-2013, 2015-2019, 2021-2024, 2025 [Blog post]
  • Quantitative Principles for Drug Development Decision-Making. Session 3: Learning and Confirming Trials: Finding and Confirming the Right Dose. American Course on Drug Development and Regulatory Sciences. Yearly, April 2021- 2025 [Blog post]
  • Career Development Panel, moderator.  Indiana CTSI Disease and Therapeutic Response Modeling Program Symposium. Feb 2023, Feb 2024, March 2025 [Blog post]
  • Tips for Virtual Networking and Social Media. ASCPT leadership Accelerator, November 2024
  • American Conference on Pharmacometrics Trainee Communication Challenge [Blog post]
    • 2024 (ACoP15): Co-Organizer, Bootcamp panelist
    • 2023 (ACoP14): Co-Organizer, moderator/host, Bootcamp panelist
    • 2022 (ACoP13): Co- Organizer, moderator/host, Bootcamp panelist
    • 2021 (ACoP12): Bootcamp panelist
    • 2020 (ACoP11): Co-Organizer, moderator/host, panelist, (winning) team coach
  • Is Pharmacometrics Limited by Industry Settings? Session co-organizer, speaker, and moderator. American Conference on Pharmacometrics ACoP15, November 2024. [Blog post]
  • Pharmacokinetic/Pharmacodynamic Modeling of Monoclonal Antibodies: A Tool for Decision-Making in Drug Development. At PHA6418: Introduction to Model Informed Drug Development Course at University of Florida Center for Pharmacometrics and Systems Pharmacology. Aug 2023, Oct 2024
  • Explore MeRGE: the Metrum Research Group Ecosystem. Workshop co-organizer and teaching assistant.  Population Approach Group in Europe (PAGE) July 2024
  • Giving an Effective Interview Seminar. You’re Hired! Resume Tips & Interviewing Techniques for Success, ASCPT Career Connect. June 2024
  • Soft Skills Aren’t SOFT… and Teamwork is WORK! Communicating M&S to a Diverse Audience for Understanding and Impact.  
  • Needs, Gaps, and Opportunities in Quantitative Medicine: A Multistakeholder Discussion on Education/Outreach, Policy Development, Stakeholder Engagement (panelist). At Streamlining Drug Development and Improving Public Health through Quantitative Medicine: An Introduction to the CDER Quantitative Medicine Center of Excellence, April 2024 [Blog post]
  • Clinical Pharmacology (Career Pathways in Industry), with Peter Bonate. Intro to Pharmacy Research 2024, Midwestern University, Chicago College of Pharmacy, Apr 2024
  • Asian-Pacific Training Course on Pharmacokinetics and Pharmacodynamics of Therapeutic Proteins. Shanghai May 2019, Suzhou March 2024
    • Target-Mediated Drug Disposition.
    • PKPD M&S: Turnover models.
    • Predicting Doses from One Indication to the Next for Canakinumab, an Anti-IL-1β Monoclonal Antibody.
    • Predicting the Human Pharmacodynamics of Monoclonal Antibodies: Implications for First-in-man Studies.
    • Pharmacokinetic/Pharmacodynamic Modeling of Monoclonal Antibodies: A Tool for Decision-Making in Drug Development.
  • Principles of Population PKPD Modeling. At ISSX 2023 Short Course: Multidisciplinary View of Modeling and Simulation: Fundamentals, Case Examples, and Future Directions. Nov 2023.
  • Communication, Negotiation, and Compromise, with Angela James. At Transitioning from Us to Them: A Soft Skills Workshop for Navigating Diverse Teams. American Conference on Pharmacometrics trainee workshop, November 2023
  • Are you ready for the shark tank?! Trainee Communication challenge, co-organizer and panelist. Lake Nona Leadership Council meeting, University of Florida.  March 2023
  • QSP: ¿Qué eS, Por favor? Iberoamerican Pharmacometrics Network (RedIF) Congress, Oct 2022
  • PMx and QSP: Compare, Contrast, Converge, and Collide– joint presentation with Matthew Riggs. Pharmacometrics and QSP: Convergence, Commonalities, and Continuities” symposium, World Conference on Pharmacometrics (WCoP) April 2022.
  • Pediatric and Special Population Studies. Clinical Pharmacology in Drug Development Training Course, University of the Pacific. Oct 2021, Oct 2022
  • Strategies & Skills For New & Future Managers. ACCP Early-stage Professional Webinar, Aug 2022
  • Teamwork Is WORK – The Art and Science of Collaboration. Critical Path Institute(C-Path) Leadership Team meeting. June 2022
  • Communication and Soft Skills… And Whatever Else You All Want To Talk About!
    • University of Maryland Career Navigation LEAP session, March 2022
    • Indiana University CTSI Disease and Therapeutic Response Modeling and Simulation meeting, Feb 2022
  • Review of the Various Model Types Commonly Used for MIDD, Part 1 and Part 2. MIDD training curriculum for FDA reviewers (later opened to the public), Dec 2021 [Blog post]
  • Changing How Managers Manage Change Management. At: Integrating Standardization and Innovation In Your Organization: Find A Workflow That Works For You!” American Conference on Pharmacometrics Pre-Conference, ACoP12, Nov 2021
  • MID3 Roller Coaster Workshop. Facilitator. ASCPT Apr 2021 and Aug 2021
  • Healthcare and Higher Podcast with Iqbal Atcha, Aug 20, 2021
  • Communication in the Age of COVID with Peter Bonate, ISoP Education Webinar. Apr 27, 2021
  • Your Authentic Self (Audio and video). “The Power of Story and Science” Podcast with David P. Otey.  Apr 7, 2021
  • Pharmacometrics: a fitting career for pharmaceutical scientists. AAPS Seminar at Howard University. March 2021
  • Presentations, posters, and Publications: Step it Up to Stand Out! AAPS Student Chapter Seminar, Howard University. Nov 2020
  • The role of MIDD in drug development for clinical bridging and alternate dosing: Prologue. AAPS PharmSci 360, Oct 2020.
  • Making the Moster of Your Poster. Rosa Drug Development Webinar. Sept 9, 2020
  • Pharmacometrics: a fitting career for quantitative scientists. University of Augusta Mathematics Department Seminar. Feb 2020
  • Pharmacometrics: Application of Mathematics, Statistics, and Computer Science (MSCS) to Pharmaceutical Development. Statistics and Data Science Seminar. University of Illinois, Chicago, Sept 2019.
  • Predicting the Human Pharmacodynamics of Monoclonal Antibodies: Implications for First-in-man Studies.
  • Pharmacokinetics and Pharmacodynamics of Protein Therapeutics. University of Tennessee Health Science Center Apr 2011-2013, 2015-2019
  • Changing Minds from “All Models are Wrong” to “Some are Useful”. ASCPT Quantitative Pharmacology Network Webinar, July 2019
  • Day in the Life of a Pharmacometrician. AAPS Forum to Connect Predictive Modelers, May 2019
  • MID3: Mission Impossible or Model-Informed, Drug Discovery and Development? Point/Counterpoint Discussions on Key Challenges session. ASCPT Annual Meeting, March 2019
    • Model Less, Communicate More. Primary Limitations To Success
    • Wrong Models Can Be Dangerous. All Models Are Wrong but Some Are Useful
  • Visualization Tools for Assessing Reliability of Quantitative Systems Pharmacology Models. Rapid Fire Presentation. AAPS PharmSci 360, Nov 2018
  • Getting Your Foot on the Rung of the Leadership Ladder. AAPS PharmSci 360, Nov 2018
  • Resistance is Futile: Changing Minds from “All Models Are Wrong” to “Some Are Useful”. Indiana CTSI Symposium on Disease and Therapeutic Response Modeling and Simulation, Nov 2018
  • How to train the next generation of Pharmacometricians and Systems Pharmacologists, speaker and panelist. Lake Nona Leadership Council Meeting, March 2018
  • Speaking into the Ether- Challenges of the Virtual Pharma Workplace with Peter Bonate. Certara Webinar, Apr 19, 2017
  • Pharmacometricians and Statisticians- Can’t We All Just Get Along? Rosa Drug Development Webinar. Feb 23, 2017
  • Mentoring Panel presenter: Student Outreach Committee (SOC). ACCP Annual Meeting Sept 2016.
  • Pharmacometricians and Statisticians- Can’t We All Just Get Along? “Bridging the Gap between Pharmacometricians and Statisticians” symposium. World Conference on Pharmacometrics (WCoP), Aug 2016
  • Introduction to M&S and principles of PK/PD modeling.
    • University of Mississippi, Apr 2016.
    •  Chicago State University AAPS Student Chapter, March 2016.
  • Role, Accountability, and Skill Sets of Pharmacometricians and Statisticians: Industry Perspective. “Enabling Environments in Which Pharmacometrics and Biostatistics Help Produce Robust Development And Regulatory Strategies” Workshop. American Conference on Pharmacometrics ACoP6 Oct 2015
  • From Student to Scientist: An Inside Look at Career Opportunities in the Pharma Industry. AAPS Student Event, May 2015
    • Overview of Pharmacokinetics, Modeling, and simulation and personal career path
    • “How Not to Get Hired” Panel Discussion: the do’s and don’ts of effective interviewing
  • Professional Development Session for Students: Effective Communication
    • AAPS Annual Meeting Oct 2015
    • American Conference on Pharmacometrics ACoP6 Oct 2015
  • Principles of Modeling and Simulation. “Five-Part Series on Fundamentals of Clinical Pharmacology for Drug Development”. DIA Webinar, Sept 2014
  • Introduction to M&S and principles of PK/PD modeling. “PK/PD Principles and Applications”. Applied Pharmaceutical Analysis Short Course, Sept 2014
  • Leveraging MBDD and business impact in a mid-size company.
    • At: Efficiencies of Resource Utilization for MBDD. AAPS Annual Meeting, Nov 2013
    • At: Is Model-based Drug Development Delivering on its Promise? Assessing the Business Impact. American Conference on Pharmacometrics May 2013
  • Integrating PK and PD Platforms to Remove the ‘Preclinical to Clinical’ Divide and Streamline Drug Development. At: Improved PK/PD Modeling & Analysis to Optimize Translation of Preclinical Data into the Clinic. 5th World PK/PD Summit, March 2013
  • Modeling and Simulation Support for Design of First-in-Man Studies. At: Minimizing Attrition by Optimizing Integration of Preclinical and Clinical Data”. 3rd Annual World PK/PD Summit: March 2012
  • Predicting Doses from One Indication to the next for canakinumab, an anti-IL-1beta monoclonal antibody. “Model Based Drug Development: Learning from One Indication to the Next” session. ACCP Annual Meeting, Sept 2011
  • Quantitative exposure – response evaluations in Preclinical and Early Clinical Development, translational activities and FIH design. “Quantitative Clinical Pharmacology throughout the Discovery and Development Continuum in Inflammation and Immunology” session. ACCP Annual Meeting, Sept 2011
  • Modeling and Simulation 101. Drug and Biologics Regulatory Training Program at Yale to scientists from the SFDA (Chinese Health Authority). Yale University, New Haven CT. Nov 2010.
  • Model-based Drug Development: Overview and Current Role in Drug Development. ACCP Annual Meeting. Sept 2010
  • PK/PD Modeling of Monoclonal Antibodies: A Tool for Decision Making in Drug Development. University of Tennessee, AAPS Visiting Scientist Program, March 2010.
  • Predicting the Human Pharmacodynamics of Monoclonal Antibodies: Implications for First in Man Studies. ISSX, Oct 2009
  • Monoclonal Antibody Modeling and Simulation. Novartis Biologics PK-PD Workshop Sept 2008.
  • Expanding the Xolair dosing table through PKPD modeling. Novartis Respiratory pre-meeting workshop, European Respiratory Society meeting. Sept 2007.
  • Phase 2a: Proof of Concept. “Satisfying Critical Dose Finding Objectives in Each Stage of the Clinical Process” workshop at the Center for Business Intelligence conference “Dose Finding in Clinical Trials”. Feb 2007
  • Modeling and Simulation: Learn to Speak the Language. AAPS Annual Meeting, Nov 2006.
  • A Comparison of Clinical Study Designs using Fixed Dosing (FD) versus Covariate Adjusted Dosing (CAD). At : “Optimizing Dose and Exposure-Response Studies: Reducing Development Time and Expense” Apr 2004.
  • A Novel Method of Combining Both Continuous and Discrete Categorical Covariates in a Single Joint Function for Generation of Realistic Virtual Patients in a Clinical Trial Simulation. “Population PK/PD on the Cutting Edge” poster- podium session. AAPS Annual Meeting Nov 2002
  • A Novel Method of Combining Both Continuous and Discrete Categorical Covariates in a Single Joint Function.  Center for Drug Development Science Clinical Trial Simulation Workshop. Washington, DC, Aug 2002

I am text block. Click edit button to change this text.

Peer Reviewed Publications

Other Publications

  • Hartford A, Fostvedt L, Waterhouse T, Goteti K, Kulkarni H, Lystig T, Millen B, Tannenbaum S, Vaddady P. Connecting ISoP with Statisticians: An Introduction to the Biopharmaceutical Section of the American Statistical Association. American Conference on Pharmacometrics ACoP14, Nov 2023.
  • Bhattacharya S, Tannenbaum S, Nielsen J, Siripuram V. Advancing quality control (QC) process in pharmacometrics using GIT.  American Conference on Pharmacometrics ACoP14, Nov 2023.
  • Heo N, Nielsen J, Tannenbaum S. Strategies for the Selection of Informed PK Sampling Timepoints in Late Phase Trials. American Conference on Pharmacometrics ACoP12, Nov 2022.
  • Desai A, Kovanda L, Lademacher C, Tannenbaum S. Dose Prediction and Confirmation using Population Pharmacokinetics and Physiologically Based Pharmacokinetics in Pediatric Patients for Isavuconazole. Accepted to (cancelled) WCoP Apr 2020
  • Braakman S, Paxson R, Tannenbaum S, Gulati A. Visualizing Parameter Source Reliability and Sensitivity for QSP Models.
    • Accepted to (cancelled) ASCPT Annual Meeting March 2020
    • ACoP10 Oct 2019
  • Gulati A, Tannenbaum S. Using visualization to address the reliability of sources of initial parameter values in a Quantitative Systems Pharmacology (QSP) model.
    • ACoP9 Oct 2018
    • AAPS PharmSci 360, Nov 2018
  • Bosman B, Tannenbaum S, Winklewski P, Den Adel M, Newgreen D, Baka-Ostrowska M. A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with Neurogenic Detrusor Overactivity (NDO). International Continence Society Annual Meeting Aug 2013
  • Ait-Oudhia S, Tannenbaum S, Lowe PJ, and Mager DE. Population Pharmacokinetic Model of Canakinumab in Patients with Active Rheumatoid Arthritis. AAPS National Biotechnology Conference May 2011
  • Ait-Oudhia S, Lowe PJ, Tannenbaum S, and Mager DE. Bridging Clinical Outcomes to Canakinumab in Rheumatoid Arthritis Patients to a Population PK/PD Model Using IL-1β Kinetics. AAPS Annual Meeting, Oct 2011
  • Roberts J, Sunkara G, Tannenbaum S, Vahn L, Chakraborty A. Ethnic Sensitivity Assessment of Canakinumab Pharmacokinetics and Pharmacodynamics in Gouty Arthritis Patients. ASCPT Annual Meeting March 2012
  • Tannenbaum S, Chakraborty A, Vaidya S, Heep M, Chaves R, Benzinger D. Pharmacokinetic Considerations for Use of Daptomycin in Patients with Renal Impairment. 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Sept 2010
  • Lowe PJ, Tannenbaum S, Gautier A, Massanari M. Omalizumab may normalize IgE production rate in patients with moderate-to-severe atopic asthma. American College of Clinical Pharmacy Annual Meeting Oct 2010
  • Tannenbaum S, Chakraborty A, Rordorf C, Lowe P. A Methodology for Model-Based Bioequivalence of Two Manufacturing Variants of a Monoclonal Antibody. ACoP2 Oct 2009
  • Pinault G, Pillai G, Steimer J-L, McDevitt H, Tannenbaum S, Buchheit V. Sharing experiences of a dedicated SAS programming group in a M&S department. ACoP2, Oct 2009
  • Tannenbaum S, Chakraborty A, Rordorf C, Gautier A, Lowe P. Pharmacokinetics of canakinumab and pharmacodynamics of IL-1β binding in patients with cryopyrin associated periodic fever syndrome. Population Approach Group in Europe (PAGE) June 2009
  • Lowe P, Tannenbaum S, Gautier A. Omalizumab (XOLAIR®) may normalize IgE production rate in patients with moderate-to-severe atopic asthma. Population Approach Group in Europe (PAGE), June 2009
  • Tannenbaum S, Gautier A, Lowe P. Relationship between omalizumab pharmacokinetics and IgE pharmacodynamics in adult and paediatric patients with moderate-to-severe persistent allergic (IgE-mediated) asthma. Population Approach Group in Europe (PAGE) June 2009
  • Tannenbaum S, Chakraborty A, Rordorf C, Gautier A, Lowe P. Pharmacokinetics of canakinumab and pharmacodynamics of IL-1β binding in patients with cryopyrin associated periodic fever syndrome and systemic juvenile idiopathic arthritis. AAPS Annual Meeting Nov 2008
  • Tannenbaum S, Gautier A, Lowe P. A Mechanism Based Binding Model for the Population Pharmacokinetics and Pharmacodynamics of ACZ885, a Monoclonal Antibody in Development for Rheumatoid Arthritis. AAPS Annual Meeting Nov 2008
  • Stoellner D, Tannenbaum S, Gautier A, Deckert F, Lowe P. On the use of a captured target biomarker to deduce the extent of binding of canakinumab to IL-1β in patients with Muckle-Wells Syndrome and rheumatoid arthritis. Monoclonal Antibodies: Cutting-edge Science for New Medicines workship. EUFEPS June 2008
  • Lowe P, Tannenbaum S, Gautier A, Jiminez P, Panalhoo Z. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.
    • European Respiratory Society Sept 2007
    •  European Academy of Allergology and Clinical Immunology, June 2008
    • AAPS Annual Meeting, Nov 2008
  • Tannenbaum S, Williams G, Sun H, Lee P, Lesko L, Temple R. A Comparison of Proposed Pharmacokinetic Modified Dose-Controlled (PKMD) versus Traditional Fixed Dose-Controlled (FD) Clinical Study Designs. Population Approach Group in Europe (PAGE) June 2007
  • Tannenbaum S, Holford N, Mould D, Lee H, Peck C. A Novel Method for Simulation of Correlated Continuous and Categorical Variables Using A Single Multivariate Distribution. Population Approach Group in Europe (PAGE) June 2005
  • Tannenbaum S, Lee P, Sun H, Williams G, Lesko L, Temple R. A Comparison of Clinical Study Designs using Fixed Dosing (FD) versus Covariate Adjusted Dosing (CAD). AAPS Annual Meeting Oct 2003
  • Tannenbaum S, Holford N, Mould D, Lee H, Peck C. Validation of a Novel Method of Combining Both Continuous and Categorical Covariates in a Single Joint Function for Clinical Trial Simulation. ASCPT Annual Meeting Apr 2003
  • Lee H, Tannenbaum S, Peck C. A Novel Method For Deriving Intersubject Variability For Baseline Hazard Rates and Relative Risks For Secondary Vascular Events, ASCPT Annual Meeting Apr 2003
  • Tannenbaum S, Kim S, Mayersohn M. Estimation of the Fractional Conversion of Cocaine to Cocaethylene When Co- Administered With Ethanol. ASCPT Annual Meeting March 2002
  • Tannenbaum S and Mayersohn M. Drugs that Undergo Saturable Elimination Can Be Allometrically Scaled: Ethanol as a Prototype Drug. AAPS Annual Meeting Oct 2001
  • Tannenbaum S and Mayersohn M. A Pharmacokinetic/Pharmacodynamic Analysis of Cocaine (C), Cocaethylene (CE), and Cocaine Plus Ethanol (C+E) in the Dog: A Literature Evaluation. Building Competitive Research Careers: A Symposium for the Arizona Biomedical Research Community, Sept 1999
  • Tannenbaum S and Mayersohn M. A Pharmacokinetic/Pharmacodynamic Analysis of Cocaine (C), Cocaethylene (CE), and Cocaine Plus Ethanol (C+E) in the Dog: A Literature Evaluation. AAPS Annual Meeting Nov. 1999
  • Tannenbaum S and Mayersohn M. A Mathematical Approach to Predicting the Approximate Dose and Time of Dosing in Humans. AAPS Annual Meeting Nov 1998
  • Tannenbaum S and Mayersohn M. A Mathematical Approach to Predicting the Approximate Dose and Time of Dosing in Humans. The Flinn Foundation Fourth Annual Biomedical Symposium. December 1998
  • Tannenbaum S, Boxenbaum H, Mayersohn M. Allometric Analysis of Organ Extraction Ratios. AAPS Annual Meeting Nov 1997
  • Tannenbaum S and Mayersohn M. Prediction of Pharmacokinetic Parameters in Humans on the Basis of Allometric Scaling using a ‘Global’ Slope. AAPS Annual Meeting Oct 1996.
  • Tannenbaum S, Sinha V, Mayersohn M. Potential Errors in the Use of Body Burden Calculations for Estimation of Toxicokinetic Parameters. Society of Toxicology Annual Meeting March 1996